PPCB (Propanc Biopharma) EBITDA Margin %: 0.00% (As of Mar. 2026)


PPCB Propanc Biopharma Inc PPCB
29 GF Score
Price $1.48
! 2 Warning Signs
View Full Analysis

What is Propanc Biopharma EBITDA Margin %?

Propanc Biopharma PPCB +1.36% 29 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates PPCB with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Propanc Biopharma ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Propanc Biopharma's EBITDA for the three months ended in Mar. 2026 was $-6.32 Mil. Propanc Biopharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Propanc Biopharma's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Propanc Biopharma  (NAS:PPCB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Propanc Biopharma EBITDA Margin % Related Terms

Propanc Biopharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Propanc Biopharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Propanc Biopharma EBITDA Margin % Chart

Propanc Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Propanc Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PPCB vs ENSC, ACUT, LSBCF: EBITDA Margin % Comparison

For the Biotechnology subindustry, Propanc Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Propanc Biopharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's EBITDA Margin % falls into.


PPCB
29GF Score
Propanc Biopharma Inc PPCB
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Propanc Biopharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Propanc Biopharma's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-58.339/0
= %

Propanc Biopharma's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-6.315/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Propanc Biopharma (PPCB) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Propanc Biopharma and its competitors. According to the industry distribution chart, Propanc Biopharma ranks #999999 out of 945 companies in the Biotechnology industry.
Is Propanc Biopharma's EBITDA Margin % too high?
Propanc Biopharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, Propanc Biopharma ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Propanc Biopharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Propanc Biopharma's EBITDA Margin % compare to ENSC and ACUT?
According to the Biotechnology industry distribution chart, Propanc Biopharma ranks #999999 out of 945 companies for EBITDA Margin %. This places Propanc Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Propanc Biopharma and its competitors. Propanc Biopharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Propanc Biopharma stock overvalued right now?
Propanc Biopharma (PPCB) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Propanc Biopharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Propanc Biopharma (PPCB), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Propanc Biopharma Business Description

Address 302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
29GF Score

Get the complete analysis for PPCB

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.48
Price